|
Posted: MAR 6, 2007
CSMG
Technologies' Live Tissue Connect Retains Top Medical
Instrument Manufacturer for Its Surgical Instruments
Corpus Christi, TX, March 6, 2007 -- CSMG Technologies,
Inc., (OTC Bulletin Board: CTUM
- News)
a technology management company focused on commercializing
tissue bonding devices, announced that their Live Tissue
Connect subsidiary has signed a contract with Ventrex,
Inc. (www.ventrexinc.com)
for manufacturing of their electrocautery hand held
surgical instruments.
Donald S. Robbins, president and CEO of CSMG, said,
"We are pleased to be working with Ventrex, Inc.
to develop product packaging, perform sterilization
validation and to manufacture Live Tissue Connect, Inc.'s
("LTC's") hand held surgical instrument. Ventrex,
Inc. is recognized throughout the medical device industry
as a leader in therapeutic electrocautery instrument
manufacturing and packaging. Live Tissue Connect, a
subsidiary, is quickly completing its sound team of
experienced medical device professionals to meet our
regulatory filing, design and manufacturing needs."
LTC's Frank D. D'Amelio added, "Ventrex was selected
as our disposable hand-instrument manufacturer of choice
due to the breadth of their manufacturing and regulatory
experience. I was impressed with their team and their
level of vertical manufacturing integration. We now
have all the necessary design and manufacturing companies
lined-up and working on all the components required
for commercialization of our first series of bipolar
tissue devices."
CSMG owns the technology and exclusive world rights
to the live tissue bonding device through Live Tissue
Connect, Inc., a subsidiary corporation formed for the
development and exploitation of the platform technology.
LTC expects to complete hand instruments, electrocautery
generator and other electrosurgery components for the
duct and vessel sealing system, meeting FDA and European
CE Mark requirements, respectively. They also expect
to start filing for approval of these devices with regulatory
entities in early 2007.
About CSMG Technologies' Tissue Welding/Bonding
Technology
The LTC tissue welding/bonding device is a platform
technology that bonds and reconnects living soft biological
tissue through fusion without the use of foreign matter
in contrast with conventional wound closing devices
such as sutures, staples, sealant, or glues.
Surgeons at 27 Ukraine hospitals and clinics are using
the tissue welding/bonding technology in clinical trials.
They have completed more than 7,000 human surgeries
using more than 80 types of open and laparoscopic surgical
procedures, demonstrating the technology is universal
in its ability to repair soft biological tissue. These
surgeries included lung, neurosurgery, nasal septum,
intestine, stomach, skin, gall bladder, liver, spleen,
blood vessels, nerves, alba linea, uterus, bladder,
gynecological, fallopian tube, ovary and testicles and
dura-matter. Cosmetic surgeries conducted with this
technology include breast reduction, breast implants,
mastopexy and abdominoplasty. The procedure involves
little or no scarring, while restoring the normal function
of the body organ or tissue.
The technology was invented and developed at the internationally
renowned E.O. Paton Institute of Electric Welding, National
Academy of Sciences of Ukraine, Kiev, Ukraine, headed
by Professor B.E. Paton. U.S., Australian, Canadian
and European Union patents have been issued, and additional
U.S. and foreign patents are pending, all owned by LTC.
About CSMG Technologies, Inc.
CSMG Technologies is a technology management company
that finances, owns, develops, licenses and markets
innovative advanced technologies and business opportunities
created in the Ukraine through a network of scientific
institutes and private organizations. CSMG is focused
on two primary subsidiaries, Live Tissue Connect, Inc.
and landfill gas processing.
For further information on CSMG Technologies and its
various subsidiaries, please visit our website at www.ctum.com.
Sign up to receive CSMG Technologies automated email
press releases and other notifications: Please go to
http://www.ctum.com/contact_information.html
and fill-in information.
This press release may contain forward-looking
information within the meaning of Section 21E of the
Securities Exchange Act of 1934 as amended (the Exchange
Act), including all statements that are not statements
of historical fact regarding the intent, belief or current
expectations of the company, its directors or its officers
with respect to, among other things: (i) the company's
financing plans; (ii) trends affecting the company's
financial condition or results of operations; (iii)
the company's growth strategy and operating strategy;
and (iv) the declaration and payment of dividends. The
words "may," "would," "will," "expect," "estimate,"
"anticipate," "believe," "intend" and similar expressions
and variations thereof are intended to identify forward-looking
statements. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance
and involve risks and uncertainties, many of which are
beyond the company's ability to control, and that actual
results may differ materially from those projected in
the forward-looking statements as a result of various
factors.
CONTACT:
ROI Group Associates, Inc.
Michael Dodge, 212-495-0744
mdodge@roiny.com
or
Bob Giordano, 212-495-0201
CSMG Technologies, Inc. - 500 No. Shoreline # 701 no.
- Corpus Christi, TX 78471
Donald S. Robbins, President and CEO
361-887-7546
K. Bruce Jones
770-955-0409
|
